Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developing
novel therapeutics targeting free fatty acid receptors for NASH, Type 2 Diabetes (T2D) and other potential indications. Caldan has arisen from a long-term collaboration between Professor Trond Ulven at the University of Southern Denmark and Professor Graeme Milligan of the University of Glasgow.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Edinburgh, Gb
- in****@****s.co.uk
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- caldantherapeutics.co.uk
- HQ
- Edinburgh
Caldan Therapeutics Questions
Caldan Therapeutics's website is caldantherapeutics.co.uk
Caldan Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/caldan-therapeutics
Caldan Therapeutics has
2 employees.
View email and phone details for 2
employees at Caldan Therapeutics.
Caldan Therapeutics's industry is
Biotechnology Research
Caldan Therapeutics's top competitors are
Resolution Therapeutics,
Cell And Gene Therapy Catapult,
Odx Innovations,
Glox Therapeutics Ltd.,
Aten Therapeutics Ltd,
Kynos Therapeutics,
Mironid® Limited,
Cytomos,
Invizius,
Causeway Therapeutics.
Caldan Therapeutics's support email address is info@caldantherapeutics.co.uk
Caldan Therapeutics's categories are Biotechnology Research
Caldan Therapeutics's founding year is 2015
